{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033281","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.138273+00:00","generated_at":"2026-05-31T15:37:42.224099+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corcept Q2 revenue up 39% to $163.8M; raises 2024 guidance to $640-670M","bullets":["Q2 revenue $163.8M, up 39% YoY; diluted EPS $0.32 vs $0.25.","2024 revenue guidance raised to $640-670M from $620-650M.","Cash and investments $492.5M at June 30, up from $451M at March 31.","NDA submission for relacorilant in Cushing's syndrome expected Q4; late-stage trial results (ROSELLA, GRADIENT, DAZALS) due by year-end.","Record number of new Korlym prescribers and patients; hypercortisolism screening expanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033281","json":"https://secwatch.observer/filing/0001628280-24-033281.json","markdown":"https://secwatch.observer/filing/0001628280-24-033281.md","text":"https://secwatch.observer/filing/0001628280-24-033281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024033281/0001628280-24-033281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024033281/cort-20240729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:37:42.224099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}